Aardvark Therapeutics, Inc. (AARD) stock
Close on Nov 11, 2026Market cap $34.80MP/E –Yield –
Aardvark Therapeutics, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$54.27M. At the latest close the market valued the company at $34.80M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $34.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.47
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$69.89M
- EPS, diluted
- -$3.21
- Free cash flow
- -$54.27M
- Book value per share
- $3.42
- Diluted shares
- 22M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $1.37
- Open
- $1.35
- Day's range
- $1.34 – $1.68
- Volume
- 388,408
- Average volume (20 days)
- 1,689,149
- 52-week range
- $0.93 – $16.60
- RSI (14 days)
- 34.5
- Volatility (1 year)
- 148.8%
- Relative volume
- 0.72×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AARD | S&P 500 | Difference | AARD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -66.6% | -2.4% | −64.2 pts | ||
| 3 months | -77.9% | -1.2% | −76.7 pts | ||
| Year to date | -87.9% | +12.3% | −100.2 pts | ||
| 1 year | -85.6% | +12.4% | −98.1 pts | ||
| 3 years | +354.3% | +78.8% | +275.5 pts | +65.6% | +21.4% |
| 5 years | +354.3% | +75.2% | +279.1 pts | +35.4% | +11.9% |
| 10 years | +354.3% | +311.1% | +43.2 pts | +16.3% | +15.2% |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aardvark Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Results
- News
About Aardvark Therapeutics
Pharmaceutical Preparations
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic conditions. The company primarily targets bitter taste receptors expressed in the gut lumen to stimulate the release of endogenous signaling molecules that help alleviate hunger. Its product candidates include ARD-101, an oral gut-restricted agonist under evaluation for hyperphagia associated with Prader-Willi Syndrome, and ARD-201, a combination therapy intended for obesity and weight regain prevention.
Company profile, executives and historyAardvark Therapeutics stock: common questions
What is Aardvark Therapeutics's stock price?
AARD closed at $1.59 on Nov 11, 2026, up 16.06% on the day. Over the past 52 weeks it traded between $0.93 and $16.60.
What is Aardvark Therapeutics's market cap?
Aardvark Therapeutics was worth $34.80M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AARD's P/E ratio?
Aardvark Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.21), so it has no meaningful P/E ratio.
How much revenue does Aardvark Therapeutics make?
Aardvark Therapeutics reported revenue of $0 for the twelve months to Jun 30, 2026.
Does Aardvark Therapeutics pay a dividend?
No. Aardvark Therapeutics has not paid a cash dividend over the last twelve months.
When does Aardvark Therapeutics report earnings next?
Aardvark Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has AARD stock performed over the past year?
Including dividends, AARD returned -85.6% over the past year, against +12.4% for the S&P 500.
How many AARD shares are sold short?
1M shares were sold short at the latest FINRA report, 8.17% of the float, or 1.0 days of average trading volume.
Who are Aardvark Therapeutics's competitors?
Companies most similar to Aardvark Therapeutics by business, industry and size include VKTX, ARTL, GPCR, VTVT, BLTE.
See a number that looks wrong?